ClinicalTrials.gg
CompletedNCT02586350Updated May 21, 2019

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

A Phase 2/3 interventional study of Anlotinib and Placebo in Medullary Thyroid Carcinoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 19 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-05-21.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Carcinoma, Medullary with a site in China — 9 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Medullary · China.

Enrollment
10th of 16
91 · median 151
Started
2015
the only one that year
Phase 2/3
Only one
of the 18
Registered
3rd of 18
by date
Lead sponsor
2 of 18
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 18 studies in Carcinoma, Medullary with a site in China, this one is the 10th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2015, is the only one in phase 2/3, and was the 3rd registered.

Carcinoma, Medullary

144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.

Browse Carcinoma, Medullary studies →

Open to participants now

9 of the 18 studies in Carcinoma, Medullary with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Medullary with a site in China, or all of them as a file.
02

Study summary

To compare the effects and safety of Anlotinib with placebo in patients with Medullary Thyroid Carcinoma.

03

Conditions studied

  • Medullary Thyroid Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated
  2. Histological documentation of medullary thyroid carcinoma(MTC),Unable to surgery(Stage IV) or ,With (using RECIST1.1)
  3. PS:0-1, of more than 6 months
  4. main organs function is normal

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with Anlotinib or VEGFR-targeted therapies(such as Vandetanib,Cabozantinib,Lenvatinib,Sunitinib,Sorafenib etc.)
  2. Subjects received radiotherapy external exposure within 3 months prior to the first dose of study drug or plan to be received any anti-cancer treatment during study
  3. Patients suffering from other currently or within 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancers and superficial bladder cancer [ Ta (non-invasive carcinoma), Tis (carcinoma in situ) and T1 (carcinoma invasion into lamina propria) ]
  4. (4.0) Grade 1 or higher non-remission toxicity induced by any other previous treatments,excluding alopecia and Grade 2 or lower neurotoxicity induced by oxaliplatin
  5. Patients with factors that could affect oral medication (such as dysphagia etc.)
  6. Patients with pleural effusion or ascites, causing respiratory syndrome (CTCAE Grade 2 or higher dyspnea [Grade 2 dyspnea refers to Shortness of breath with a small amount of activities, affecting Instrumental activities of daily life])
  7. Patients underwent major surgical treatment,open or significant traumatic injury within 28 days prior to assignment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Anlotinib

    Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.

    Drug: Anlotinib

  • Placebo comparator
    Placebo

    Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.

    Drug: Placebo

Interventions

  • Also known as: Anlotinib p.o. qd

  • DrugPlacebo

    Placebo p.o. qd

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    To compare the Progression-free Survival (PFS) of subjects with medullary thyroid carcinoma(MTC) with Anlotinib versus Placebo.

    Time frame: Date of randomization to the date of disease progression (measured every 6 weeks) or death (whichever occurs first) as determined by blinded independent imaging review(assessed up to 24 months)

Secondary outcomes

  1. Overall Response Rate (ORR)

    To compare Overall Response Rate (ORR) (Complete and Partial Responses, CR and PR) of subjects treated with Anlotinib versus Placebo.

    Time frame: Date of randomization to the date of disease progression (measured every 6 weeks) or death (assessed up to 24 months)

07

Study locations

19 sites
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Beijing Tongren Hospital
    Beijing, Beijing, China
  • Peking Union Medical College Hospital
    Beijing, Beijing, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing 404100, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
  • Gansu Province Tumor Hospital
    Lanzhou, Gansu, China
  • Sun Yat-Sen University Cancer Center
    Guozhou, Guangdong, China
  • Harbin medical university affiliated tumor hospital
    Harbin, Heilongjiang, China
  • Henan Province Tumor Hospital
    Zhengzhou, Henan, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Hunan Province Tumor Hospital
    Changsha, Hunan, China
  • Jiangsu province tumor hospital
    Nanjing, Jiangsu, China
  • Jilin Cancer Hospital
    Changchun, Jilin 132000, China
  • Liaoning Province Tumor Hospital
    Shenyang, Liaoning, China
  • Cancer Hospital of Fudan University
    Shanghai, Shanghai, China
  • West China Hospital Of Sichuan University
    Chongqing, Sichuan 400010, China
  • 20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital .
    Tianjin, Tianjin 300600, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Sep 2018 and a completion of Sep 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2015
First posted
Oct 26, 2015
Start
Jul 2015
Primary completionActual
Sep 30, 2018
CompletionActual
Sep 30, 2018
Last update
May 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02586350
Responsible party
Sponsor
First posted
Oct 26, 2015
Start date
Jul 2015
Primary completion
Sep 30, 2018
Completion
Sep 30, 2018
Last update
May 21, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anlotinib

Start the discussion